 Heidelberg, Germany, February 3, 2021 Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has entered into a clinical research collaboration with Roche to explore the combination of Affimeds innate cell engager ICE AFM24 with Roches PD-L1 checkpoint inhibitor atezolizumab Tecentriq. 